The scope of oncology research is often high, and the complexity of clinical trial designs and study designs is increasing. Reports currently show that the success rate of investigational compounds approved for clinical use in cancer is the lowest of any disease, and only 6.7% are thought to be approved for these diseases. Cancer drugs are being studied in Phase I studies. In oncology, there are key differences in clinical trials.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
